A Safety Study of SGN-CD47M in Patients With Solid Tumors

A Safety Study of SGN-CD47M in Patients With Solid Tumors

Publication date: May 21, 2019

This trial will study SGN-CD47M to find out whether it is an effective treatment for different types of solid tumors and what side effects (unwanted effects) may occur. The study will have two parts. Part A of the study will find out how much SGN-CD47M should be given for treatment and how often. Part B of the study will use the dose found in Part 1 and look at how safe and effective the treatment is.

Concepts Keywords
Adenocarcinoma Pharmacokinetics
Anemia Chemotherapy
Autoimmune Dose
Autoimmune Disease Treatment of cancer
Biologics Seattle Genetics
Biomarker Radiation therapy
Biopsy Chemotherapy
Birth Control Oncology
Blood Transfusion Radiobiology
Breast Carcinoma Cancer
Carcinoma Clinical medicine
Central Nervous System Medicine
Chemotherapy Platelet transfusion
Corticosteroids Blood transfusion
Cytologically Chemotherapy
Fungal Infection Radiotherapy
Hemolytic Anemia Birth control
Hepatitis Immune hemolytic anemia
Histologically Immunotherapy
HIV HIV
Idiopathic Thrombocytopenic Purpura Unstable angina
Immunodeficiency Treatment solid tumors
Immunosuppressive Medications Active autoimmune disease
Immunotherapy History sickle anemia
Lung
Malignancies
Malignancy
Maximum Tolerated Dose
Melanoma
Meningitis
Metastases
Metastasis
Metastatic
Myocardial Infarction
Neoplastic
Oncology
Pharmacodynamic
Pharmacokinetics
Platelet
Progressive
Radiotherapy
Refractory
Sickle
Soft Tissue Sarcoma
Sperm
Squamous Carcinoma
Targeted Therapy
Tolerability
Toxicity
Transfusion
Unstable Angina
Viral
Virus

Semantics

Type Source Name
disease DOID Carcinoma
gene UNIPROT ALG3
disease MESH Carcinoma
gene UNIPROT NR4A2
disease DOID myocardial infarction
disease MESH myocardial infarction
disease DOID unstable angina
disease MESH unstable angina
disease MESH fungal infection
gene UNIPROT IK
gene UNIPROT DYRK3
disease MESH Carcinomatous meningitis
disease DOID idiopathic thrombocytopenic purpura
disease MESH idiopathic thrombocytopenic purpura
disease DOID hemolytic anemia
disease MESH hemolytic anemia
disease MESH sickle cell anemia
disease DOID sickle cell anemia
disease MESH latent tuberculosis
disease MESH infections
pathway BSID Hepatitis C
disease DOID hepatitis C
disease MESH hepatitis C
pathway BSID Hepatitis B
disease DOID hepatitis B
disease MESH hepatitis B
gene UNIPROT SIRPA
gene UNIPROT CD47
disease MESH metastasis
pathway BSID Melanoma
disease DOID Melanoma
disease MESH Melanoma
disease DOID Gastric carcinoma
disease DOID pancreatic adenocarcinoma
disease DOID Ovarian carcinoma
disease DOID Breast carcinoma
disease MESH Breast carcinoma
disease MESH Tumors
disease MESH Soft tissue sarcoma
disease MESH Colorectal carcinoma
disease DOID Colorectal carcinoma
disease DOID Non-small cell lung carcinoma
disease DOID Head and neck squamous cell carcinoma

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *